How We Help
NET Cancer is the FASTEST growing class of CANCER worldwide
HELP US HELP OTHERSNeuroendocrine Tumours (NETs) Overview
- Neuroendocrine tumours (NETs) are abnormal growth of cells (neoplasms) that arise from cells of the diffuse neuroendocrine system.
- NETs are considered complex tumours because both tumor growth and hormonal function must be addressed.
- NETs are most common in the lung or gastrointestinal system, but they can also originate in other parts of the body such as the thyroid, thymus, pancreas, adrenals, paraganglia, ovaries and testes.
- NETs are classified as functional (produce hormones that cause symptoms), or non-functional (may or may not produce hormones and do not cause hormonal symptoms).
- The cause of NETs is currently unknown.
Contact Us For Live Support
Support Lines:
416-628-3189
Toll Free: 1-844-628-6788
Latest CNETS Canada News
68Ga-DOTATATE PET scan in Ontario
68Ga-DOTATATE PET scan in Ontario Cancer Care Ontario has announced that as of April 1st, 2019, Ontario patients with neuroendocrine tumours (NETs) meeting eligibility criteria are able to have their 68Ga-DOTATATE PET scan in Ontario [...]
2019 National NET Patient Conference LIVE-STREAM
Join CNETS Canada 2019 National NET Patient Conference's video & audio conference by clicking the following link: https://freeman.meetngreet.ca/join/x1GxoRj3UO 2019 NATIONAL NET PATIENT CONFERENCE LIVE-STREAM Saturday April 6, 2019 from 8:30 am - 4:30 pm [...]
CNETS Canada Board of Directors Announcement
As we start 2019 we bid farewell to a long-time board member and welcome three new board members to CNETS Canada’s Board of Directors. We extend our heartfelt gratitude to Silvia Steinhilber as she retires [...]
Jackie Herman Elected To The Board of INCA
Our very own Jackie Herman, CNETS Canada President was elected to the International Neuroendocrine Cancer Alliance (INCA) on January 30th, 2019. INCA welcomed 2 new Directors to the INCA Board: Jackie Herman – Director [...]
Toronto’s CN Tower Lights Up Black & White!
November 10, 2018 - Toronto's CN Tower lights up black & white in honour of NET Cancer Awareness Day
Health Canada approves XERMELO™ (telotristat ethyl)
Health Canada approves XERMELO™ (telotristat ethyl) for the treatment of adult patients suffering from refractory carcinoid syndrome diarrhea(1) "XERMELOTM is a novel, orally administered, inhibitor of the enzyme tryptophan hydroxylase and is designed to reduce [...]